{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05329649",
            "orgStudyIdInfo": {
                "id": "VX21-CTX001-151"
            },
            "secondaryIdInfos": [
                {
                    "id": "2021-002173-26",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Vertex Pharmaceuticals Incorporated",
                "class": "INDUSTRY"
            },
            "briefTitle": "Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)",
            "officialTitle": "A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease",
            "therapeuticArea": [
                "Other"
            ],
            "study": "evaluation-of-safety-and-efficacy-of-in-pediatric-participants-with-severe-sickle-cell-disease-scd"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-05-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-04-07",
            "studyFirstSubmitQcDate": "2022-04-07",
            "studyFirstPostDateStruct": {
                "date": "2022-04-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Vertex Pharmaceuticals Incorporated",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "CRISPR Therapeutics",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001)."
        },
        "conditionsModule": {
            "conditions": [
                "Sickle Cell Disease",
                "Hydroxyurea Failure",
                "Hydroxyurea Intolerance",
                "Hemoglobinopathies",
                "Hematological Diseases"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 15,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "CTX001",
                    "type": "EXPERIMENTAL",
                    "description": "CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive single infusion of CTX001 through central venous catheter.",
                    "interventionNames": [
                        "Biological: CTX001"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "CTX001",
                    "description": "Administered by intravenous infusion following myeloablative conditioning with busulfan.",
                    "armGroupLabels": [
                        "CTX001"
                    ],
                    "otherNames": [
                        "Exagamglogene autotemcel",
                        "Exa-cel"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Proportion of Participants who do not Have any Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months (VF12)",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Proportion of Participants Free from Inpatient Hospitalization for Severe VOCs for at Least 12 Months (HF12)",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Relative Reduction in Annualized Rate of Severe VOCs",
                    "timeFrame": "From Baseline up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Duration of Severe VOC Free in Participants who Have Achieved VF12",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Relative Reduction in Annualized Rate of Inpatient Hospitalizations for Severe VOCs",
                    "timeFrame": "From Baseline up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Proportion of Participants With Sustained Fetal Hemoglobin (HbF) \u226520 Percent (%) for at Least 3 Months",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Proportion of Participants With Sustained HbF \u226520% for at Least 6 Months",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Proportion of Participants With Sustained HbF \u226520% for at Least 12 Months",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Proportion of Alleles With Intended Genetic Modification Present in Peripheral Blood Over Time",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Proportion of Alleles With Intended Genetic Modification Present in CD34+ Cells of the Bone Marrow Over Time",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "timeFrame": "From Signing of Informed Consent up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Proportion of Participants With Engraftment (First day of 3 Consecutive Measurements of Absolute Neutrophil Count [ANC] \u2265500 per Microliter [mcgL] on 3 Different Days)",
                    "timeFrame": "Within 42 Days After CTX001 Infusion"
                },
                {
                    "measure": "Time to Engraftment",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Incidence of Transplant-related Mortality (TRM) Within 100 Days After CTX001 Infusion",
                    "timeFrame": "Within 100 Days After CTX001 infusion"
                },
                {
                    "measure": "Incidence of TRM Within 12 Months After CTX001 Infusion",
                    "timeFrame": "Within 12 Months After Infusion"
                },
                {
                    "measure": "Incidence of All-cause Mortality",
                    "timeFrame": "From Signing of Informed Consent up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Relative Reduction in Annualized Duration of Hospitalization for Severe VOCs",
                    "timeFrame": "From Baseline up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Proportion of Participants With Sustained HbF \u226530% for at Least 3 Months",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Proportion of Participants With Sustained HbF \u226530% for at Least 6 Months",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Proportion of Participants With Sustained HbF \u226530% for at Least 12 Months",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Time for Participants to Reach HbF \u226520%",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Time for Participants to Reach HbF \u226530%",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Relative Reduction from Baseline in Annualized Volume and Episodes of RBC Transfusions for SCD-related indications starting after Month 12 post-CTX001 infusion",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "HbF Concentrations Over Time",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Hemoglobin (Hb) Concentrations Over Time",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Change in Reticulocyte Count Over Time",
                    "timeFrame": "From Baseline up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Change in Indirect Bilirubin Over Time",
                    "timeFrame": "From Baseline up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Change in Haptoglobin Over Time",
                    "timeFrame": "From Baseline up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Proportion of Participants with Detectable Haptoglobin Over Time",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Change in Lactate Dehydrogenase (LDH) Over Time",
                    "timeFrame": "From Baseline (Pre-infusion) up to 24 Months After CTX001 Infusion"
                },
                {
                    "measure": "Proportion of Participants with Normalized LDH Over Time",
                    "timeFrame": "Up to 24 Months After CTX001 Infusion"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Diagnosis of severe SCD as defined by:\n\n  * Documented SCD genotypes\n  * History of at least two severe VOCs events per year for the previous two years prior to enrollment\n* Hydroxyurea (HU) failure unless HU intolerant\n* Eligible for autologous stem cell transplant as per investigators judgment\n\nKey Exclusion Criteria:\n\n* A willing and healthy 10/10 human leukocyte antigen (HLA)-matched related donor\n* Prior hematopoietic stem cell transplant (HSCT).\n* Clinically significant and active bacterial, viral, fungal, or parasitic infection\n\nOther protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "2 Years",
            "maximumAge": "11 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Medical Information",
                    "role": "CONTACT",
                    "phone": "617-341-6777",
                    "email": "medicalinfo@vrtx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Atrium Health Levine Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                },
                {
                    "facility": "Children's Hospital of Philadelphia",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "St. Jude Children's Research Hospital",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Memphis",
                    "state": "Tennessee",
                    "zip": "38105",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.14953,
                        "lon": -90.04898
                    }
                },
                {
                    "facility": "The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "University Hospital Duesseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology",
                    "status": "RECRUITING",
                    "city": "Dusseldorf",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.22172,
                        "lon": 6.77616
                    }
                },
                {
                    "facility": "Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS",
                    "status": "RECRUITING",
                    "city": "Rome",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 41.89193,
                        "lon": 12.51133
                    }
                },
                {
                    "facility": "St Mary's Hospital",
                    "status": "RECRUITING",
                    "city": "London",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000755",
                    "term": "Anemia, Sickle Cell"
                },
                {
                    "id": "D000006453",
                    "term": "Hemoglobinopathies"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000745",
                    "term": "Anemia, Hemolytic, Congenital"
                },
                {
                    "id": "D000000743",
                    "term": "Anemia, Hemolytic"
                },
                {
                    "id": "D000000740",
                    "term": "Anemia"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4085",
                    "name": "Anemia, Sickle Cell",
                    "asFound": "Sickle Cell Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "asFound": "Hematological Diseases",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9539",
                    "name": "Hemoglobinopathies",
                    "asFound": "Hemoglobinopathies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4070",
                    "name": "Anemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M9547",
                    "name": "Hemolysis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4073",
                    "name": "Anemia, Hemolytic",
                    "relevance": "LOW"
                },
                {
                    "id": "M4075",
                    "name": "Anemia, Hemolytic, Congenital",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T5229",
                    "name": "Sickle Cell Anemia",
                    "asFound": "Sickle Cell Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M5336",
                    "name": "Busulfan",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}